Study shows efficiency of new gastric cancer drug

According to an international experiment a report is published in The Lancet, shows that is one of the largest types III trials are in second line treatment of gastric cancer are lending positive hopes to find proper treatment for the problem. If all went well this could be a real help towards finding proper treatment of the disease. This study was investigated over 355 patients with the help of advanced gastric cancer. Out of them 238 received treatment with ramucirumab, rest 117 received placebo. When looked into details the ramucirumab treatment group showed better and improved median survival as compared to the other group. Previously the standard care for advanced gastric cancer was known as first-line treatment that is based on chemotherapy that uses to offer a median survival of 8 to 10 months. Now it is in totally improved form. The scientists are happy with the progress but they are still searching out better options to get better and fast treatment for gastric cancer.